Patient characteristics associated with prescribing of a newly introduced drug: the case of rofecoxib
- 11 March 2005
- journal article
- research article
- Published by Springer Nature in European Journal of Clinical Pharmacology
- Vol. 61 (2) , 157-159
- https://doi.org/10.1007/s00228-005-0891-z
Abstract
Objective To identify socio-demographic characteristics of the first patients receiving a new drug—rofecoxib. Outcome measurement Patients starting on rofecoxib or another non-steroidal anti-inflammatory drug (NSAID) and who had not received any NSAIDs the 90 days prior to starting. Results Starting on rofecoxib was associated with an increasing age (OR in age 80 years and older 8.7; 95% CI 6.7–11.2), a poor self-perceived health (OR=2.4; 95% CI 1.8–3.3), female gender (OR=1.4; 95% CI 1.2–1.6), private insurance (OR=1.3; 1.1–1.5) and previous acetaminophen use (OR=1.3; 1.1–1.7). Conclusion This study noted that specific patient characteristics were associated with getting rofecoxib prescribed shortly after marketing. General practitioners should be aware of selectively prescribing new drugs to specific patients because it may place patients at unintentional and avoidable risk.Keywords
This publication has 6 references indexed in Scilit:
- Monitoring health inequalities through general practice: the Second Dutch National Survey of General PracticeEuropean Journal of Public Health, 2005
- Influences on GPs' decision to prescribe new drugs--the importance of who says whatFamily Practice, 2003
- A clinical audit of the prescribing of celecoxib and rofecoxib in Australian rural general practiceBritish Journal of Clinical Pharmacology, 2002
- NSAIDS and selective COX-2 inhibitors: competition between gastroprotection and cardioprotectionThe Lancet, 2001
- Prescriber profile and post-marketing surveillanceThe Lancet, 1993
- Channelling of controlled release formulation of ketoprofen (Oscorel) in patients with history of gastrointestinal problems.Journal of Epidemiology and Community Health, 1992